NCT07877337|RecruitingDMC
Microcurrent Therapy and the Post-Exercise Physiological Response (MENS_PE)
MENS_PE
Loading search results
MENS_PE
Sponsor study identifier
interventional
20
1 country
1
Study Start
October 15, 2026
Actual (reported)Primary Completion
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 10, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this clinical trial is to find out whether microcurrent therapy changes blood levels of creatine kinase, a marker of muscle stress, during the first 48 hours after exercise in military personnel. The main question is: Do creatine kinase levels after exercise differ between people who receive active microcurrent therapy and those who receive a sham treatment? Twenty participants will complete a standardized exercise session. Participants will be randomly assigned to one of two groups: 10 will use an active microcurrent device, and 10 will use a sham device for the same period after exercise. The sham device looks and lights up like the active device but delivers no microcurrents. Researchers will measure creatine kinase before exercise and 24 and 48 hours afterward, then compare how levels change in the two groups. Investigators will also measure blood lactate and perceived effort shortly after exercise, before either device is applied. Participants will report any difficulties using the device, discomfort, effects on sleep or rest, and unwanted effects.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 10, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 30, 2026
Actual (reported)October 15, 2026
Actual (reported)October 16, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 10, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Serum creatine kinase (CK) concentration.
Unit: U/L. Definition: Serum CK concentration will be measured at baseline and during the post- exercise recovery period at 24 and 48 hours. Baseline CK will be calculated as the mean of two measurements obtained one day before and on the day of the exercise protocol. The primary analysis will evaluate whether the CK concentrations over time differs between the active microcurrent and sham groups.
Baseline, 24 hours, and 48 hours after exercise.
Participant-perceived feasibility of microcurrent treatment administration
Immediately after the microcurrent treatment period.
Blood lactate concentration
Pre-exercise, immediately post-exercise, and 30 minutes post-exercise.
Change in perceived exertion after exercise
Immediately post-exercise and 30 minutes post-exercise.
Participant and assessor blinding success
Immediately after completion of the study intervention.
Occurrence of adverse events
Immediately after the microcurrent treatment period.
Participants randomized to the active microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. Participants will then apply active transcutaneous microcurrent devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period. The devices will deliver microcurrent output while in use. The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.
Participants randomized to the sham microcurrent group will complete the standardized exercise protocol and the immediate and 30-minute post-exercise assessments before beginning treatment. The participants will then apply sham devices to both legs. Each leg will receive at least seven hours of device application per day throughout the post-exercise treatment period. The sham device is the same model as the active device, but it has been modified by an engineer. Its indicator light illuminates in the same way as the active device, while the microcurrent-generating function remains inactive and no microcurrent is delivered. The devices will otherwise be applied in exactly the same way in both groups, preserving participant and outcome-assessor blinding. The study team will record any difficulties with application, adverse events, effects on sleep or rest, and perceived unpleasantness.
Prolonged post-exercise transcutaneous microcurrent therapy using an active microcurrent patch applied for minium 7 hours following exercise to promote recovery from exercise-induced muscle fatigue.
Prolonged post-exercise sham transcutaneous microcurrent intervention using a modified device engineered to reproduce the appearance and operating indicators of the active device, including illumination of the indicator light, while delivering no microcurrent output. The sham device is applied following the same procedure and for the same duration as the active intervention.
Campus de Toledo de la Universidad de Castilla-La Mancha (UCLM)
Toledo, 45071, Spain
Juan Avendaño-Coy, PhD
University of Castilla-La Mancha
First Submitted
September 30, 2026
First Posted
October 16, 2026
Study Start
October 15, 2026
Actual (reported)Primary Completion
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
November 1, 2026
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 10, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 28, 2026
Record last verified: 2026-10
It is planned to make the anonymized datasets publicly available through the Zenodo repository.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: